Objective Response to First-Line Treatment as a Predictor of Overall Survival in Metastatic Breast Cancer: A Retrospective Analysis from Two Centers over a 25-Year Period.

The purpose of this study was to study the efficacy of subsequent treatment lines for metastatic breast cancer (MBC), as well as the association between radiologic objective response rate (ORR) and overall survival (OS). In this retrospective study, consecutive patients treated for MBC in two centers in Greece from January 1, 1992, to December 31, 2016, were identified and clinicopathologic data regarding tumor characteristics and administered treatments were collected. The efficacy per treatment line in terms of ORR, progression-free survival (PFS) and OS, as well as the prognostic value of ORR at first line were investigated. A total of 977 patients with MBC were identified; 950 received any treatment. At first line, ORR was 43.5%, PFS 11.4 months (95% CI 10.4-12.4), and median OS 52.4 months (95% CI 47.7-57.1). Lower ORR and shorter PFS were observed with each subsequent line. Median OS was significantly longer for patients that had an objective response at first line, 61.9 months (95% CI 51.1-69.7) for responders versus 41.3 months (95% CI 44.1-63.3) for nonresponders ( Late treatment lines for MBC seem to have limited efficacy, while response to first-line therapy is associated with long-term survival. The latter should be considered in the treatment strategy of patients with MBC.

Informations de copyright

Copyright © 2021 by S. Karger AG, Basel.

Déclaration de conflit d'intérêts

Alexios Matikas, Maria Perraki, Dora Hatzidaki, Konstantinos Kalbakis, and Michail Nikolaou have no conflicts of interest to disclose. Emmanouil Kontopodis has received research grants from Amgen and Astellas, honoraria from Bristol Myers Squibb, Roche, Merck Sharp & Dohme (MSD), and Angelini Pharma and travel grants from MSD, Aenorasis, and Genesis Pharma. Athanasios Kotsakis has received research grants and honoraria for participation in advisory boards from MSD, Roche, Bristol, and Astra Zeneca. Vasilios Georgoulias has received research grants and honoraria for participation in advisory boards from Amgen, Pfizer, Astra Zeneca, Roche, Sanofi-Aventis, and Novartis.